Lyra Therapeutics, Inc. (LYRA)
NASDAQ: LYRA · IEX Real-Time Price · USD
6.22
-0.31 (-4.75%)
At close: Mar 28, 2024, 4:00 PM
6.50
+0.28 (4.50%)
After-hours: Mar 28, 2024, 5:28 PM EDT

Lyra Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 202320222021202020192018
Revenue
1.561.360.29001.24
Revenue Growth (YoY)
14.31%378.25%----
Gross Profit
1.561.360.29001.24
Selling, General & Admin
19.0617.5614.219.694.493.53
Research & Development
48.0338.829.6912.5212.034.98
Other Operating Expenses
1.591.320000
Operating Expenses
68.6857.6743.922.2116.528.5
Operating Income
-67.12-56.31-43.62-22.21-16.52-7.26
Interest Expense / Income
00000-0.04
Other Expense / Income
-4.5-1.04-0.1-0.08-0.21-1.19
Pretax Income
-62.62-55.27-43.51-22.13-16.31-6.03
Income Tax
0.060.010000
Net Income
-62.68-55.28-43.51-22.13-16.31-6.03
Shares Outstanding (Basic)
503013900
Shares Outstanding (Diluted)
503013900
Shares Change
64.72%132.83%51.17%4150.62%21.68%-
EPS (Basic)
-1.26-1.83-3.35-2.59-82.23-36.79
EPS (Diluted)
-1.26-1.83-3.35-2.59-82.23-36.79
Free Cash Flow
-64.35-43.55-29.21-22.92-13.97-6.68
Free Cash Flow Per Share
-1.29-1.44-2.25-2.67-69.10-40.20
Gross Margin
100.00%100.00%100.00%--100.00%
Operating Margin
-4308.09%-4131.03%-15303.51%---583.52%
Profit Margin
-4023.11%-4055.61%-15267.72%---484.65%
Free Cash Flow Margin
-4130.36%-3195.08%-10247.37%---536.74%
EBITDA
-62.34-54.2-42.51-22.03-16.28-5.98
EBITDA Margin
-4001.48%-3976.38%-14916.49%---480.95%
Depreciation & Amortization
0.281.0710.10.030.08
EBIT
-62.62-55.27-43.51-22.13-16.31-6.07
EBIT Margin
-4019.32%-4054.66%-15267.72%---487.54%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).